NCT02108964
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02108964
Title A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | NLD | ESP | DEU | CAN

Facility Status City State Zip Country Details
Massachusetts General Hospital Mass General Boston Massachusetts 02114 United States Details
Memorial Sloan Kettering Oncology Department New York New York 10017 United States Details
Novartis Investigative Site Toronto Ontario M5G 2M9 Canada Details
Novartis Investigative Site Berlin 13125 Germany Details
Novartis Investigative Site Cologne 50937 Germany Details
Novartis Investigative Site Nagoya Aichi-ken 464 8681 Japan Details
Novartis Investigative Site Fukuoka Fukuoka 811-1395 Japan Details
Novartis Investigative Site Zoetermeer NL-2722 EP Netherlands Details
Novartis Investigative Site Singapore 168583 Singapore Details
Novartis Investigative Site Seoul 03080 South Korea Details
Novartis Investigative Site Seoul 05505 South Korea Details
Novartis Investigative Site Barcelona Catalonia 08035 Spain Details
Novartis Investigative Site Madrid 28041 Spain Details
Novartis Investigative Site Taipei 10002 Taiwan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field